Business
Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352
Collaborative efforts are aimed at using Lantern’s AI platform to accelerate and sharpen the drug development of TTC-352. The collaboration will utilize
About this update from Lantern Pharma Inc.
[{"type":"text","content":"\n\nCollaborative efforts are aimed at using Lantern’s AI platform to accelerate and sharpen the drug development of TTC-352.\n\n\nThe collaboration will utilize Lantern’s AI-based capabilities and RADR® platform to uncover efficacy-associated biological signatures and biomarkers to advance the clinical development and strategic positioning of TTC Oncology’s leading drug candidate, TTC-352.\n\n\nPhase 2 ready candidate, TTC-352, is a novel, first- and best-in-class selective human estrogen receptor (ER) partial agonist (ShERPA) for the treatment of patients with metastatic ER+ breast cancer.\n\n\nLantern is receiving exclusive rights to license TTC-352 during an exclusive option period, which includes rights to intellectual property generated during the collaboration.\n\n\n DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (\"AI\") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it has entered into a research and development collaboration with TTC Oncology. The collaboration will focus on leveraging RADR® AI insights to advance TTC Oncology’s first- and best-in-class drug candidate TTC-352 for recurrent ER+ breast cancer patients and additional patient populations potentially identified by RADR®. In US women, breast cancer remains the most commonly diagnosed cancer and second leading cause of cancer related deaths. ER+ breast cancers are estimated to account for 75-80% of all breast cancer cases and can have a recurrence rate between 13% and 41%. Globally, the treatment of ER+ breast cancer is estimated to have a $44 billion market potential by 2027.\n\n”It is of the utmost importance for cancer drug development to understand targeted tumor biology and mechanisms of resistance in order to select the patient population that will benefit the most from novel therapy. We expect that by using Lantern’s RADR® AI platform it can save us time and costs in the further successful clinical development of TTC-352 while providing important information for precision patient selection,” said Dr. Arkadiusz Dudek, TTC Oncology Chief Medical Officer.\n\nThe collaboration will be powered by RADR®’s 25+ billion oncology-focused data points, 200+ ad...